{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:02:27Z","timestamp":1780549347762,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.radonc.2025.111158","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:06:47Z","timestamp":1758575207000},"page":"111158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-3611","authenticated-orcid":false,"given":"Peter S.","family":"Palencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-2023","authenticated-orcid":false,"given":"Shayan","family":"Smani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-2877","authenticated-orcid":false,"given":"Keervani","family":"Kandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nethusan","family":"Sivanesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime A.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-7528","authenticated-orcid":false,"given":"Sanjay","family":"Aneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.radonc.2025.111158_b0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111158_b0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"7547","key":"10.1016\/j.radonc.2025.111158_b0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.radonc.2025.111158_b0020","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111158_b0025","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v12i8.5687","article-title":"Definitive local treatment for metastatic prostate cancer: a national cancer database analysis","volume":"12","author":"Whalen","year":"2024","journal-title":"Med Res Arch"},{"issue":"6","key":"10.1016\/j.radonc.2025.111158_b0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111158_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study","volume":"67","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.radonc.2025.111158_b0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.radonc.2025.111158_b0045","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111158_b0050","unstructured":"!!! INVALID CITATION !!! 9;."},{"issue":"6","key":"10.1016\/j.radonc.2025.111158_b0055","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.radonc.2025.111158_b0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, Version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.radonc.2025.111158_b0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.radonc.2025.111158_b0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.radonc.2025.111158_b0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111158_b0080","doi-asserted-by":"crossref","unstructured":"16. Bossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design. Lancet 23 2024;404(10467):2065-2076. doi:10.1016\/s0140-6736(24)01865-8.","DOI":"10.1016\/S0140-6736(24)01865-8"},{"issue":"6","key":"10.1016\/j.radonc.2025.111158_b0085","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.radonc.2025.111158_b0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of (68)Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study","volume":"61","author":"Sonni","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.radonc.2025.111158_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"(68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10231","key":"10.1016\/j.radonc.2025.111158_b0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.radonc.2025.111158_b0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:14:33Z","timestamp":1780546473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402505162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S016781402505162X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111158","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111158"}}